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To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the
clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this
approach is to discover subgroups of patients that are characterized by a good or poor treatment outcome. Dennis
and colleagues have identified distinct pretreatment gene expression profiles in affected synovial tissue specimens
and a tissue type-related systemic protein pattern which are associated with a positive or negative clinical outcome
to monotherapy with adalumimab (anti-TNFα) and tocilizumab (anti-IL-6 receptor). These observations assign
biological pathways associated with response outcome and provide evidence for the existence of systemic,
easy-to-measure predictive biomarkers for clinical benefit of these biologics.In rheumatoid arthritis (RA), therapies with biologics
targeting TNFα, IL-6 receptor, T-cell co-stimulation, and
B cells are successfully used worldwide. Since not all pa-
tients benefit from these specific therapies, there is a
strong unmet need for pretreatment predictions on ther-
apy outcome. This concept of personalizing treatment
has raised interest in the discovery of clinically applic-
able pretreatment biomarkers to make predictions on
outcome before the start of treatment. In this issue of
Arthritis Research & Therapy, Dennis and colleagues [1]
report on two tissue type-related blood-based protein
biomarkers that are associated with the clinical response
to adalimumab (anti-TNFα) and tocilizumab (anti-IL-6
receptor).
Global gene expression profiling is a powerful method
for biomarker discovery purposes and has proven to be
useful in the identification of potentially useful bio-
markers in cancer [2,3]. In RA, this approach yielded a
potentially useful blood-based biomarker for the predic-
tion of outcome of B-cell depletion therapy using rituxi-
mab [4]. However, very inconsistent results were
obtained for TNF blockers, raising skepticism about the* Correspondence: c.verweij@vumc.nl
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2014clinical utility of the reported gene signatures [5,6].
These controversial results for TNF blockers may indi-
cate the complex interplay between pathogenesis and
anti-TNF pharmacology in RA.
Dennis and colleagues [1] describe a multistep process
to identify predictive biomarkers in serum for adalimu-
mab and tocilizumab. Their study is based on the prem-
ise of the existence of different molecular synovial
phenotypes between patients with RA, as has been noted
before [7]. Firstly, the authors identified four clearly dis-
tinct molecular synovial phenotypes by using global ex-
pression profiling. Gene ontology analysis indicated the
existence of two inflammatory axes: one with a lymphoid
phenotype, characterized by B-cell abundance, and an-
other with a myeloid phenotype, characterized by acti-
vated M1-monocyte enrichment. The remaining two
subtypes represented a low inflammatory phenotype and
a fibroblast activation phenotype.
Secondly, only the myeloid phenotype appeared to be
associated with European League Against Rheumatism
good-versus-poor response to the TNF blocker inflixi-
mab. Receiver operating characteristic (ROC) analysis
revealed an area under the curve (AUC) of 77% for the
myeloid-associated gene set, indicating that pretreatment
transcript levels of the synovial myeloid phenotype could
potentially enrich for good responders to TNF blockers.
Thirdly, to translate these findings to a more easily
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intercellular adhesion molecule 1 (ICAM1), enriched in
the lymphoid and myeloid synovial phenotypes, respect-
ively, each encoding a soluble product that could serve
as a systemic biomarker. Subsequent measurements of
CXCL13 and soluble ICAM1 (sICAM1) in pretreatment
serum samples from the ADACTA (ADalimumab
ACTemrA) trial (comparing adalimumab with toci-
lizumab) revealed that CXCL13low/sICAM1high patients
had the highest American College of Rheumatology
(ACR)-based clinical responses to adalimumab after
24 weeks, whereas CXCL13high/sICAM1low patients had
the highest responses to tocilizumab. ROC AUC values
for the individual biomarkers reached 65%, based on
ACR 50% improvement criteria response outcome.
The scientific value of these findings comes from the
identification of two distinct highly inflammatory syn-
ovial tissue subtypes that appear to be key to identifying
anti-TNFα and anti-IL-6 receptor responders. This cor-
roborates findings from others of a correlation between
baseline macrophages and TNFα levels with clinical re-
sponse [8,9]. Successful action of TNFα blockers may
rely on the presence of a myeloid phenotype represent-
ing inflammatory M1 monocytes, which may constitute
a key lineage in TNFα-activated nuclear factor-kappa-B-
driven synovitis. The TNFα-regulated and membrane-
shed ICAM1 appears to be an exponent of the myeloid
tissue phenotype. In contrast, the B-cell dominant highly
inflammatory lymphoid phenotype appears to be select-
ively driven by the IL-6/IL-6 receptor pathway and
its JAK/STAT-associated transcription factor STAT3.
Surprisingly, this phenotype was not characterized by se-
lective expression of IL-6 or IL-6-related genes (IL-6R,
IL-6ST/gp130, and STAT3), indicative of the pleiotropic
role of IL-6 in different processes of human biology as-
sociated with different tissue subsets. Synovium-derived
circulating CXCL13 as a B-cell chemoattractant could
explain B-cell trafficking into lymphoid phenotype tis-
sues. Since CXCL13 is selectively expressed by follicular
dendritic cells, it remains to be established whether the
lymphoid phenotype is associated with the presence of
ectopic germinal centers.
Although the results of Dennis and colleagues [1] are
scientifically important and demonstrate the importance
of gene expression profiling in the search for predictive
biomarkers, the individual patient-based ROC analyses
show only modest predictive ability and therefore weak
clinical utility. As mentioned by the authors, the problem
for the weak performance may lie in the linear rather than
discrete distribution of the synovial phenotypes. There-
fore, further refinement and incorporation of additional
biomarkers may improve the clinical utility.
All together, these results indicate that molecular phe-
notyping of patients with RA clearly contributes to thedevelopment of a personalized medicine approach for
TNFα and IL-6 blockade. Moreover, detailed analysis of
specific patterns may lead to new therapeutic avenues.
Usage of predictive biomarkers in combination with
those for other biologics, such as rituximab, might lead
to an early-triage approach for enrichment of those pa-
tients most likely to respond to a distinct biologic in RA.
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